Department of Microbiology and Immunology, University of North Carolina, Chapel Hill, North Carolina, USA.
PLoS One. 2012;7(12):e52054. doi: 10.1371/journal.pone.0052054. Epub 2012 Dec 14.
Islet transplantation provides a "cure" for type 1 diabetes but is limited in part by recurrent autoimmunity mediated by β cell-specific CD4(+) and CD8(+) T cells. Insight into the T cell receptor (TCR) repertoire of effector T cells driving recurrent autoimmunity would aid the development of immunotherapies to prevent islet graft rejection. Accordingly, we used a multi-parameter flow cytometry strategy to assess the TCR variable β (Vβ) chain repertoires of T cell subsets involved in autoimmune-mediated rejection of islet grafts in diabetic NOD mouse recipients. Naïve CD4(+) and CD8(+) T cells exhibited a diverse TCR repertoire, which was similar in all tissues examined in NOD recipients including the pancreas and islet grafts. On the other hand, the effector/memory CD8(+) T cell repertoire in the islet graft was dominated by one to four TCR Vβ chains, and specific TCR Vβ chain usage varied from recipient to recipient. Similarly, islet graft- infiltrating effector/memory CD4(+) T cells expressed a limited number of prevalent TCR Vβ chains, although generally TCR repertoire diversity was increased compared to effector/memory CD8(+) T cells. Strikingly, the majority of NOD recipients showed an increase in TCR Vβ12-bearing effector/memory CD4(+) T cells in the islet graft, most of which were proliferating, indicating clonal expansion. Importantly, TCR Vβ usage by effector/memory CD4(+) and CD8(+) T cells infiltrating the islet graft exhibited greater similarity to the repertoire found in the pancreas as opposed to the draining renal lymph node, pancreatic lymph node, or spleen. Together these results demonstrate that effector/memory CD4(+) and CD8(+) T cells mediating autoimmune rejection of islet grafts are characterized by restricted TCR Vβ chain usage, and are similar to T cells that drive destruction of the endogenous islets.
胰岛移植为 1 型糖尿病提供了“治愈”方法,但部分受到β细胞特异性 CD4(+)和 CD8(+)T 细胞介导的自身免疫反应的限制。深入了解驱动自身免疫反应的效应 T 细胞的 T 细胞受体(TCR)谱将有助于开发免疫疗法以防止胰岛移植物排斥。因此,我们使用多参数流式细胞术策略来评估参与糖尿病 NOD 小鼠受者胰岛移植物自身免疫性排斥的 T 细胞亚群的 TCR 可变β(Vβ)链谱。幼稚 CD4(+)和 CD8(+)T 细胞表现出多样化的 TCR 谱,这在 NOD 受者所有检查的组织中均相似,包括胰腺和胰岛移植物。另一方面,胰岛移植物中的效应记忆 CD8(+)T 细胞库主要由一到四个 TCR Vβ 链主导,并且特定的 TCR Vβ 链使用因受者而异。同样,胰岛移植物浸润的效应记忆 CD4(+)T 细胞表达有限数量的常见 TCR Vβ 链,尽管与效应记忆 CD8(+)T 细胞相比,通常 TCR 谱多样性增加。引人注目的是,大多数 NOD 受者在胰岛移植物中显示 TCR Vβ12 阳性的效应记忆 CD4(+)T 细胞增加,其中大多数细胞处于增殖状态,表明克隆扩增。重要的是,浸润胰岛移植物的效应记忆 CD4(+)和 CD8(+)T 细胞的 TCR Vβ 使用与在胰腺中发现的库相比,与引流肾淋巴结、胰腺淋巴结或脾脏中的库更为相似。这些结果表明,介导胰岛移植物自身免疫排斥的效应记忆 CD4(+)和 CD8(+)T 细胞的特征是 TCR Vβ 链使用受限,并且与驱动内源性胰岛破坏的 T 细胞相似。